RNA5SP323: A Potential Drug Target and Biomarker (G100873589)

Target Name: RNA5SP323

NCBI ID: G100873589

RNA5SP323

Other Name(s): RN5S323 | RNA, 5S ribosomal pseudogene 323

RNA5SP323: A Potential Drug Target and Biomarker

RNA5SP323 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell cycle and has been shown to play a role in various diseases, including cancer. In this article, we will discuss the biology of RNA5SP323, its potential as a drug target, and its potential as a biomarker for various diseases.

Biology of RNA5SP323

RNA5SP323 is a non-coding RNA molecule that is expressed in various tissues and cells of the body. It is a key regulator of the cell cycle and has been shown to play a role in the regulation of cell growth, apoptosis, and cancer progression. RNA5SP323 is composed of 257 amino acid residues and has a calculated molecular weight of 31 kDa.

RNA5SP323 is expressed in various tissues and cells of the body, including the brain, heart, liver, and pancreas. It is highly expressed in the brain and has been shown to play a role in the regulation of neuronal excitability and synaptic plasticity. RNA5SP323 has also been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancer.

Potential as a Drug Target

RNA5SP323 has been identified as a potential drug target due to its unique biology and its involvement in various diseases. One of the reasons for its potential as a drug target is its involvement in the regulation of the cell cycle. RNA5SP323 is a key regulator of the G1 phase of the cell cycle and has been shown to play a role in the regulation of cell growth and apoptosis.

In addition, RNA5SP323 has been shown to play a role in the regulation of angiogenesis, which is the process by which new blood vessels are formed. This is important because new blood vessels are a major contributor to the development and progression of many diseases, including cancer.

RNA5SP323 has also been shown to play a role in the regulation of inflammation and immune responses. This is important because inflammation and immune responses are involved in the development and progression of many diseases, including cancer.

Potential as a Biomarker

RNA5SP323 has also been shown to have potential as a biomarker for various diseases. One of the reasons for its potential as a biomarker is its involvement in the regulation of the cell cycle. RNA5SP323 is a key regulator of the G1 phase of the cell cycle and has been shown to play a role in the regulation of cell growth and apoptosis.

In addition, RNA5SP323 has been shown to play a role in the regulation of angiogenesis, which is the process by which new blood vessels are formed. This is important because new blood vessels are a major contributor to the development and progression of many diseases, including cancer.

RNA5SP323 has also been shown to play a role in the regulation of inflammation and immune responses. This is important because inflammation and immune responses are involved in the development and progression of many diseases, including cancer.

Conclusion

In conclusion, RNA5SP323 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its biology and its involvement in various diseases make it an attractive target for further research. Further studies are needed to determine its potential as a drug and to develop biomarkers for various diseases.

Protein Name: RNA, 5S Ribosomal Pseudogene 323

The "RNA5SP323 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNA5SP323 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets